Composition and method for preserving or culturing ocular cells

US2021207088A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2021207088-A1
Application numberUS-201917269278-A
CountryUS
Kind codeA1
Filing dateAug 30, 2019
Priority dateAug 31, 2018
Publication dateJul 8, 2021
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present disclosure provides a composition and method for preserving ocular cells. More specifically, the present disclosure provides a composition for preserving ocular cells, or culturing the cells after preservation, comprising albumin and dimethyl sulfoxide, and a cell formulation comprising the ocular cells, albumin, and dimethyl sulfoxide, and a treatment/prevention method using the same. The present disclosure also provides a method of preserving corneal endothelial cells, comprising suspending ocular cells in the composition to provide a suspension and freezing the suspension. In some embodiments, ocular cells are corneal cells (e.g., corneal endothelial cells).

First claim

Opening claim text (preview).

1 .- 30 . (canceled) 31 . A method for preserving ocular cells, comprising: suspending the ocular cells in a composition comprising albumin and dimethyl sulfoxide to provide a suspension; and freezing the suspension. 32 . The method of claim 31 , wherein the ocular cells are suspended in the suspension in a concentration of about 1×10 3 to about 1×10 8 cells/mL. 33 . The method of claim 31 , wherein the freezing the suspension comprises freezing without pre-freezing. 34 . The method of claim 33 , wherein the freezing without pre-freezing comprises freezing rapidly at about −80° C. 35 .- 70 . (canceled) 71 . The method of claim 31 , wherein the ocular cells comprise corneal cells. 72 . The method of claim 31 , wherein the ocular cells comprise corneal endothelial cells. 73 . The method of claim 31 , wherein the composition further comprises a saccharide. 74 . The method of claim 31 , wherein the composition further comprises a phosphate ion. 75 . The method of claim 31 , wherein the composition further comprises a metal ion. 76 . The method of claim 75 , wherein the metal ion is selected from the group consisting of a calcium ion, a magnesium ion, an iron ion, a zinc ion, a copper ion, an aluminum ion, and any combination thereof. 77 . The method of claim 31 , wherein the composition further comprises (i) a calcium ion and magnesium or (ii) calcium, magnesium, and copper. 78 . The method of claim 31 , wherein the albumin has a concentration of about 0.01 to about 25% (w/w) in the composition. 79 . The method of claim 31 , wherein the dimethyl sulfoxide has a concentration of about 0.1 to about 50% (w/w) in the composition. 80 . The method of claim 75 , wherein the metal ion has a concentration of about 0.0000001 to 5% (w/w) in the composition. 81 . The method of claim 31 , wherein the composition further comprises (i) about 0.1% (w/w) calcium and magnesium in the composition or (ii) about 0.1 to about 5% (w/w) calcium, magnesium, and copper in the composition. 82 . The method of claim 73 , wherein the saccharide has a concentration of about 0.1 to about 10% (w/w) in the composition. 83 . The method of claim 31 , wherein the composition is Bambanker®. 84 . The method of claim 31 , wherein the ocular cells comprise corneal endothelial cells, and the method further comprises: preserving the suspension, and administering the preserved suspension to a subject. 85 . The method of claim 84 , wherein the preserving comprises cryopreserving the suspension. 86 . The method of claim 84 , wherein the corneal endothelial cells are not cultured prior to administering to the subject.

Assignees

Inventors

Classifications

  • Physiologically active agents, e.g. antioxidants or nutrients · CPC title

  • Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue · CPC title

  • Sugars · CPC title

  • C12N5/0621Primary

    Eye cells, e.g. cornea, iris pigmented cells (photoreceptors C12N5/062) · CPC title

  • Calcium; Ca chelators; Calcitonin · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2021207088A1 cover?
The present disclosure provides a composition and method for preserving ocular cells. More specifically, the present disclosure provides a composition for preserving ocular cells, or culturing the cells after preservation, comprising albumin and dimethyl sulfoxide, and a cell formulation comprising the ocular cells, albumin, and dimethyl sulfoxide, and a treatment/prevention method using the sa…
Who is the assignee on this patent?
The Doshisha
What technology area does this patent fall under?
Primary CPC classification C12N5/0621. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu Jul 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).